Tango Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Tango Therapeutics, Inc. (NASDAQ: TNGX) is a clinical-stage biotechnology company dedicated to discovering and developing the next generation of precision oncology medicines. The company leverages the genetic principle of synthetic lethality to target tumor suppressor gene loss in defined patient populations with high unmet medical needs. Tango's lead clinical program is vopimetostat (TNG462), a highly potent and selective, once-daily, methylthioadenosine (MTA)-cooperative PRMT5 inhibitor selective for MTAP-deleted cancers. Additionally, the company is advancing TNG456, a brain-penetrant PRMT5 inhibitor targeting glioblastoma and other central nervous system (CNS) cancers, and TNG260, a CoREST inhibitor designed to reverse immune evasion in STK11-mutant lung cancers.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing the rapid advancement of the MTA-cooperative PRMT5 inhibitor vopimetostat into Phase 3 development. Following strong Phase 1/2 combination data with Revolution Medicines' daraxonrasib, the company plans to initiate a randomized-controlled Phase 3 trial in first-line MTAP-deleted pancreatic cancer.
Expected impact: Aims to establish a chemotherapy-free treatment option for patients with MTAP-deleted, RAS-mutant pancreatic cancer.
Developing TNG456, a next-generation PRMT5 inhibitor structurally optimized to cross the blood-brain barrier, for the treatment of MTAP-deleted glioblastoma and other central nervous system (CNS) malignancies.
Expected impact: Addresses a high-unmet-need oncology segment with potential to expand the addressable market to CNS cancers.
Discontinuing lower-priority or toxic programs, such as the USP1 inhibitor TNG348 (due to liver toxicity) and the PRMT5 inhibitor TNG908, to reallocate capital and operational resources toward high-priority MTAP-deleted and CNS programs (vopimetostat and TNG456).
Expected impact: Reduces R&D burn rate on discontinued assets and focuses clinical execution on candidates with the highest probability of success.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Originally established to discover and develop targeted immune evasion cancer therapies using Tango's CRISPR-enabled functional genomics platform. Although active research activities under the collaboration were truncated in late 2025, the partnership remains strategically important as agreements for all future milestones and royalties on licensed programs continue in full effect.
Terms: Gilead has the right to option up to 15 programs, with potential opt-in, extension, and milestone payments of up to $410 million per program, plus low double-digit tiered royalties on net sales.
Evaluating the combination of Tango's PRMT5 inhibitor vopimetostat with Revolution's RAS(ON) inhibitors (daraxonrasib and zoldonrasib) in patients with MTAP-deleted, RAS-mutant solid tumors.
Terms: Clinical supply and collaboration agreement to evaluate combination therapies; specific financial terms not disclosed.
Initiating a Phase 1/2 clinical trial evaluating the combination of vopimetostat and Erasca's pan-RAS inhibitor ERAS-0015.
Terms: Clinical supply agreement; specific financial terms not disclosed.